Lycia Therapeutics raises $75M Series D to advance protein degradation candidates for food allergy and Graves' disease toward early proof-of-concept data.
Bay Area biotech Lycia Therapeutics is refueling with $75 million for its protein degradation platform co-founded by Nobel laureate Carolyn Bertozzi.
The company snagged the …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Lys Therapeutics Raises More Than €25 Million to Advance LYS241 Toward Clinical Development in Neurology
The team behind Exscientia's $60M Allcyte acquisition just raised $5M from Daphni to build their own drugs — TFN
Lexaria's Animal Study GLP-1-A26-1 Has Begun Dosing on Schedule
Lilly's retatrutide has been offered to a single person via 'compassionate use' program
Small-Cap ProQR Therapeutics Secures Funding From Eli Lilly On Early Trial Success - ProQR Therapeutics (
Zymeworks acquires struggling Theravance for $929M
Lys Therapeutics Raises More Than €25 Million to Advance LYS241 Toward Clinical Development in Neurology
Ethyreal Bio emerges from stealth with $101M to develop ETHY-001, a TSHR-targeting antibody for Graves' disease and thyroid eye…
Latus Bio raised $42 million as it prepares to seek FDA approval to start a clinical trial for its gene therapy for Huntington's…
Oblenio Bio raises $62M Series B led by Pfizer Venture Investments to advance LBL-051, a trispecific TCE targeting BCMA, CD19,…
Newly published data convinced AstraZeneca to conduct a sprawling late-stage program for its GLP-1 pill. Elsewhere, Bausch + Lomb…
Polaryx Therapeutics (NASDAQ: PLYX) stock climbs on Thursday following a $10M private placement to launch its Phase 2 SOTERIA…
